H.C. Wainwright raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $74.00 (from $69.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular DystrophyJuly 12, 2018 7:10 AM Acceleron Pharma (XLRN) PT Raised to $62 at UBSJuly 10, 2018 8:01 AM Piper Jaffray Downgrades Acceleron Pharma (XLRN) to NeutralJuly 10, 2018 6:31 AM Acceleron (XLRN) option implied volatility flat into Phase III Believe results July 10, 2018 5:24 AM After-Hours Stock Movers 07/09: (OCX) (XLRN) (HEAR) Higher; (AQXP) (SPRO) (WHD) Lower (more...)July 9, 2018 5:54 PM Celgene (CELG), Acceleron (XLRN) Report Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-ThalassemiaJuly 9, 2018 4:53 PM Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-ThalassemiaJuly 9, 2018 4:52 PM